Kura Oncology (NASDAQ:KURA) Downgraded to Sell Rating by StockNews.com

StockNews.com cut shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a sell rating in a research report released on Wednesday morning.

KURA has been the topic of a number of other research reports. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price on shares of Kura Oncology in a research report on Wednesday, November 13th. Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. JMP Securities reissued a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a report on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a report on Wednesday, November 6th. Finally, Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and cut their price target for the stock from $26.00 to $19.00 in a research report on Monday, October 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Kura Oncology has a consensus rating of “Moderate Buy” and a consensus price target of $28.83.

Kura Oncology Stock Performance

Shares of KURA stock opened at $15.91 on Wednesday. The business has a fifty day moving average of $18.28 and a 200 day moving average of $19.82. Kura Oncology has a 1 year low of $9.06 and a 1 year high of $24.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Institutional Investors Weigh In On Kura Oncology

Institutional investors have recently modified their holdings of the business. Assenagon Asset Management S.A. boosted its position in Kura Oncology by 50.1% during the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock worth $35,653,000 after purchasing an additional 577,732 shares in the last quarter. Vanguard Group Inc. boosted its stake in Kura Oncology by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after purchasing an additional 28,212 shares during the last quarter. Sofinnova Investments Inc. grew its holdings in shares of Kura Oncology by 64.4% during the second quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock worth $16,992,000 after buying an additional 323,303 shares in the last quarter. Armistice Capital LLC raised its position in shares of Kura Oncology by 14.7% in the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after buying an additional 302,000 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Kura Oncology in the first quarter valued at about $110,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.